Qiagen N.V. QGEN

$44.75 +2.71 (6.45%)

Valuation

Market cap
8,663,393,000
Revenue TTM
$2,090,000,000
Net income TTM
$424,880,000
PE ratio
18.07
Forward PE
17.99
Profit margin
20.33%
Debt to equity
0.49

Trading

Volume
4,557,400
Avg volume
2,583,934
Day's range
$42.18 – $45.60
Shares out
206,075,000
Stochastic %K
77%
Beta
0.61
Analysts
Sell
Price target
$45.40

Price

Company profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary samp...

Show more

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
31 77 355 6600
Website
https://www.qiagen.com
Address
Hulsterweg 82, Venlo, Netherlands

Latest news

Stocktwits

KryptonResearch14 Oct 3, 11:58 PM
$QGEN Friday's 6.5% pop to 44.75 wasn't the FDA headline. It was the Betaville "uncooked" alert traders were passing around: at least one potential buyer is in advanced talks to acquire Qiagen at a "realistic premium." The scaffolding is real. Qiagen has had Moelis and Goldman Sachs running a strategic review since March. CTFN said two parties entered formal due diligence in August. The names linked along the way: KKR, EQT, Advent, TPG, Bain. Manager Magazin reported Qiagen wants at least 50 a share. From Friday's close, that's about a 12% premium. Underneath it was a real product beat too: the FDA cleared the QIAstat-Dx gram-negative sepsis panel on Sept 28, completing the bloodstream-infection menu at 33 pathogen targets and 28 resistance markers, all inside an hour. The 2020 precedent: Thermo Fisher walked away from a 43-euro offer when shareholders rebelled. Landing the premium is one thing; getting holders to accept it is another.
0 replies
Mrbullsociety Oct 2, 7:25 PM
Someone wants to buy Qiagen, and traders noticed. A fresh report says takeover talks for the diagnostics giant are heating up, and $QGEN is up 7% today. Mystery buyer, premium pending.
0 replies
Theflash88 Oct 2, 4:15 PM 0 replies
Theflash88 Oct 2, 4:02 PM
$VERA Time to buy. Also Check out $QGEN
0 replies
AsherLev Oct 2, 3:52 PM
$QGEN never understood why anyone would sell at this point
0 replies
Theflash88 Oct 2, 2:48 PM
$QGEN $60 minimum.
0 replies
Dirtyari Sep 30, 12:20 AM
$QGEN volume building crossing moving averages, fundametal good, a no brainer at this price
0 replies
AsherLev Sep 18, 1:29 AM
$QGEN need at least 55$/s for a takeover.
0 replies